Comment on this story
Feb 22, 2012 — The U.S. Food and Drug Administration has questions about the safety and legality of AeroShot, the inhalable caffeine product released last month. So does the American Academy of Pediatrics.|
|
n p r n e w s
More from NPR
May 24, 2012 — Do you know your tundra from your taiga? The final round of the 2012 National Geographic Bee is being held Thursday, with students between the fourth and eighth grades testing their knowledge of countries, canals, and lava lakes. See how you would have done in the preliminary rounds.
May 23, 2012 — The fallout from Facebook's initial public offering continues to spread, moving from trading screens to potentially the courtroom. Some of the investors who bought shares of the company filed a lawsuit alleging that Facebook and underwriter Morgan Stanley concealed information about Facebook's expected performance.
May 23, 2012 — Fauquier Hospital in Warrenton, Va., offers services not usually found in your average hospital. Not only is every one of its patient rooms a private one, it offers food cooked and delivered to order, and hand massages. But experts say it's the actual involvement of patients and families in their own care that sets it apart.
May 23, 2012 — The rule, instituted to improve sanitation, applies to bathrooms in tourist spots such as parks, railway stations, supermarkets and malls.
May 23, 2012 — In the past week, President Obama and House Speaker John Boehner have begun a new round of sparring over the U.S. debt ceiling. It's part of a number of problems involving debt, taxes and spending that are all slated to come to a head in early 2013. And solutions aren't likely before Election Day.
 A woman holds an AeroShot inhalable caffeine device in Boston. (AP) A Puff Of Controversy Over Inhalable Caffeineby Allison Aubrey Feb 22, 2012 — The U.S. Food and Drug Administration has questions about the safety and legality of AeroShot, the inhalable caffeine product released last month. So does the American Academy of Pediatrics.Comments |
Since we introduced you to AeroShot, a product that delivers a blast of caffeine through an inhaler, a few months back, it seems a lot of folks — mostly around college campuses in New York and Boston — have tried the quick pick-me-up. But now the U.S. Food and Drug Administration has questions. And so does the American Academy of Pediatrics. Lots of them. The FDA says it will review the safety and legality of AeroShot. Controversy can sometimes be good for sales. A spokesperson for the company says demand has shot up and the product is currently sold out — at least online. AeroShot is the brainchild of Harvard professor David Edwards, and the company, called Breathable Foods, is led by Harvard College graduate Tom Hadfield. In a statement, Hadfield says he's confident that the FDA review "will conclude that AeroShot is a safe, effective product that complies with FDA regulations." The FDA review comes after Sen. Charles Schumer, D-N.Y., raised concerns over AeroShot's potential use as a "party enhancer." "We need to make sure that AeroShot does not become the next Four Loko by facilitating dangerous levels of drinking among teenagers and college students," Schumer wrote in a statement. Another safety concern is whether the AeroShot particles could enter the lungs. According to the product's website, the powder reaches the mouth where it is swallowed and ingested. But the American Academy of Pediatrics has questioned this claim. "While your website claims that AeroShot absolutely does not enter the lungs, it is unlikely that none of the powder can enter the trachea and the large bronchi," writes AAP President Robert Block, in a letter to Hadfield. "If some product does enter the lungs, the fast absorption of caffeine into the body could have serious potential health effects." The AAP also has concerns about the effect of the product on asthma. Block also questions what data Hadfield has to support the claim that AeroShot is safe for children ages 12 and above. (The AAP discourages the nonmedical use of caffeine by all adolescents and young adults.) FDA spokesperson Tamara Ward tells The Salt that the review will determine whether a violation of the Federal Food, Drug, and Cosmetic Act has occurred, and whether regulatory action is warranted. Copyright 2012 National Public Radio. To see more, visit http://www.npr.org/. 9(MDAxNzgwMTg5MDEyMTQ4Nzc4MjdiNWVmMw004)) Source: NPR Copyright 2012 NPR - For Personal Use Only
Adirondack News Fund Founding Supporters: Paul Smith's College, The College of the Adirondacks · Wildlife Conservation Society · Adirondack Medical Center Foundation · Adirondack Museum · Niagara Mohawk Foundation · Schumann Foundation · John A. Sellon Charitable Trust · several anonymous individual donors |
